CURX earnings analysis
What we found in CURX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q extract does not include the income statement, balance sheet, cash flow statement, MD&A, or segment disclosures, so revenue, margins, EPS, cash flow, and working-capital trends cannot be assessed. The principal disclosed issue is that disclosure controls and procedures were not effective as of the end of the reporting period. The company reported 0 pending legal proceedings and 0 unregistered equity sales, but provided no quantitative guidance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- No Pending Legal Proceedings
- The company reported 0 pending legal proceedings involving the company or specified related parties in the filing.
- No Unregistered Equity Sales
- There were 0 unregistered equity sales during the period covered by the Quarterly Report.
- No Insider Trading Plan Changes
- No directors or officers adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the three months ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ineffective Disclosure Controls
- As of the end of the period covered by the Quarterly Report, management concluded that disclosure controls and procedures were not effective to provide reasonable assurance over timely recording, processing, summarization, reporting, and communication of required information.
- Risk-Factor Update Unavailable
- The filing states that Item 1A risk-factor disclosure is not required because the company is a smaller reporting company, so the provided 10-Q does not identify specific changes versus the prior filing.
- Control Remediation Not Evident
- The company states that no changes during the period covered by the Quarterly Report materially affected, or were reasonably likely to materially affect, internal control over financial reporting; however, disclosure controls remained ineffective as of June 30, 2026.
What they said about what is next.
The provided 10-Q extract contains no quantitative revenue or EPS outlook. Numeric guidance is not provided.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- Curanex Pharmaceuticals reported no revenue in Q1 2026, consistent with the same quarter in 2025. The company recorded a significant net loss of $3,150,228, up from a loss of $137,583 in the prior year, reflecting…
- 10-K · March 30, 2026
- Curanex is a development-stage botanical-drug company advancing its lead candidate Phyto-N through preclinical CMC and toxicology work toward an IND targeted for Q4 2026. The company completed a GMP pilot-scale batch in…
- 10-Q · November 17, 2025
- Curanex reported no revenue and a Q3 2025 net loss of $954,059 (three months ended September 30, 2025) versus a net loss of $91,166 in Q3 2024; diluted EPS was $(0.04) for the quarter. The company completed an IPO and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CURX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever